The cardiac sympathetic co-transmitter galanin reduces acetylcholine release and vagal bradycardia: Implications for neural control of cardiac excitability

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 3, 2012, Pages 667-676

  Herring, Neil ^a   Cranley, James ^a   Lokale, Michael N ^a   Li, Dan ^a   Shanks, Julia ^a   Alston, Eric N ^b   Girard, Beatrice M ^c   Carter, Emma ^a   Parsons, Rodney L ^c   Habecker, Beth A ^b   Paterson, David J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Acetylcholine; Autonomic nervous system; Co transmitters; Heart rate; Sympathetic; Vagus

Indexed keywords

ACETYLCHOLINE; CHOLINE ACETYLTRANSFERASE; GALANIN; GALANIN RECEPTOR 1; NEUROPEPTIDE Y; TYROSINE 3 MONOOXYGENASE;

ACETYLCHOLINE RELEASE; ANIMAL TISSUE; ARTICLE; AUTONOMIC INNERVATION; BRADYCARDIA; CONTROLLED STUDY; FEMALE; GUINEA PIG; HEART ATRIUM; HEART MUSCLE EXCITABILITY; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINUS NODE; STELLATE GANGLION; VAGUS NERVE STIMULATION;

ACETYLCHOLINE; ANIMALS; BRADYCARDIA; CHOLINERGIC NEURONS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FEMALE; GALANIN; GENE EXPRESSION; GUINEA PIGS; HEART; HEART ATRIA; NEUROPEPTIDE Y; POSTSYNAPTIC POTENTIAL SUMMATION; PROTEIN KINASE C; RECEPTORS, GALANIN; RECEPTORS, NEUROPEPTIDE Y; STELLATE GANGLION; VAGUS NERVE;

CAVIA;

EID: 84857629613     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.11.016     Document Type: Article

References (61)

1. Kummer W. Galanin- and neuropeptide Y-like immunoreactivities coexist in paravertebral sympathetic neurones of the cat. Neurosci Lett 1987, 78:127-131.
2. Warner M.R., Levy M.N. Sinus and atrioventricular nodal distribution of sympathetic fibers that contain neuropeptide Y. Circ Res 1990, 67:713-721.
3. Burnstock G. Autonomic neurotransmission: 60years since Sir Henry Dale. Annu Rev Pharmacol Toxicol 2009, 49:1-30.
4. Potter E.K., Smith-White M.A. Galanin modulates cholinergic neurotransmission in the heart. Neuropeptides 2005, 39:345-348.
5. Warner M.R., Levy M.N. Neuropeptide Y as a putative modulator of the vagal effects on heart rate. Circ Res 1989, 64:882-889.
6. Herring N., Paterson D.J. Neuromodulators of peripheral cardiac sympatho-vagal balance. Exp Physiol 2009, 94:46-53.
7. Cohn J.N., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311:819-823.
8. Kleiger R.E., Miller J.P., Bigger J.T., Moss A.J. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987, 59:256-262.
9. La Rovere M.T., Bigger J.T., Marcus F.I., A Mortara, PJ Schwartz Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998, 351:478-484.
10. Nolan J., Batin P.D., Andrews R., Lindsay S.J., Brooksby P., Mullen M., et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998, 98:1510-1516.
11. Maisel A.S., Scott N.A., Motulsky H.J., Michel M.C., Boublik J.H., Rivier J.E., et al. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med 1989, 86:43-48.
12. Hulting J., Sollevi A., Ullman B., Franco-Cereceda A., Lundberg J.M. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res 1990, 24:102-108.
13. Ullman B., Hulting J., Lundberg J.M. Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction. Eur Heart J 1994, 15:454-461.
14. Schwertfeger E., Klein T., Vonend O., Oberhauser V., Stegbauer J., Rump L.C. Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:455-461.
15. Manabe N., Foldes F.F., Torocsik A., Nagashima H., Goldiner P.L., Vizi E.S. Presynaptic interaction between vagal and sympathetic innervation in the heart: modulation of acetylcholine and noradrenaline release. J Auton Nerv Syst 1991, 32:233-242.
16. Nakatsuka H., Nagano O., Foldes F.F., Nagashima H., Vizi E.S. Effects of adenosine on norepinephrine and acetylcholine release from guinea pig right atrium: role of A1-receptors. Neurochem Int 1995, 27:345-353.
17. Herring N., Lokale M.N., Danson E.J., Heaton D.A., Paterson D.J. Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway. J Mol Cell Cardiol 2008, 44:477-485.
18. Smith-White M.A., Iismaa T.P., Potter E.K. Galanin and neuropeptide Y reduce cholinergic transmission in the heart of the anaesthetised mouse. Br J Pharmacol 2003, 140:170-178.
19. Ilebekk A., Bjorkman J.A., Nordlander M. Influence of endogenous neuropeptide Y (NPY) on the sympathetic-parasympathetic interaction in the canine heart. J Cardiovasc Pharmacol 2005, 46:474-480.
20. Warner M.R., Senanayake P.D., Ferrario C.M., Levy M.N. Sympathetic stimulation-evoked overflow of norepinephrine and neuropeptide Y from the heart. Circ Res 1991, 69:455-465.
21. Smith-White M.A., Herzog H., Potter E.K. Role of neuropeptide Y Y(2) receptors in modulation of cardiac parasympathetic neurotransmission. Regul Pept 2002, 103:105-111.
22. Diaz-Cabiale Z., Parrado C., Narvaez M., Millon C., Puigcerver A., Fuxe K., et al. Neurochemical modulation of central cardiovascular control: the integrative role of galanin. EXS 2010, 102:113-131.
23. Calupca M.A., Vizzard M.A., Parsons R.L. Origin of pituitary adenylate cyclase-activating polypeptide (PACAP)-immunoreactive fibers innervating guinea pig parasympathetic cardiac ganglia. J Comp Neurol 2000, 423:26-39.
24. Dawson T.A., Li D., Woodward T., Barber Z., Wang L., Paterson D.J. Cardiac cholinergic NO-cGMP signaling following acute myocardial infarction and nNOS gene transfer. Am J Physiol Heart Circ Physiol 2008, 295:H990-H998.
25. Tompkins J.D., Parsons R.L. Exocytotic release of ATP and activation of P2X receptors in dissociated guinea pig stellate neurons. Am J Physiol Cell Physiol 2006, 291:C1062-C1071.
26. Merriam L.A., Locknar S.A., Girard B.M., Parsons R.L. Somatic ATP release from guinea pig sympathetic neurons does not require calcium-induced calcium release from internal stores. Am J Physiol Cell Physiol 2010, 299:C836-C843.
27. Wang L., Li D., Plested C.P., Dawson T., Teschemacher A.G., Paterson D.J. Noradrenergic neuron-specific overexpression of nNOS in cardiac sympathetic nerves decreases neurotransmission. J Mol Cell Cardiol 2006, 41:364-370.
28. Zvarova K., Vizzard M.A. Changes in galanin immunoreactivity in rat micturition reflex pathways after cyclophosphamide-induced cystitis. Cell Tissue Res 2006, 324:213-224.
29. Young B.A., Girard B.M., Parsons R.L. Neurturin suppresses injury-induced neuronal activating transcription factor 3 expression in cultured guinea pig cardiac ganglia. J Comp Neurol 2008, 508:795-805.
30. Sears C.E., Choate J.K., Paterson D.J. Inhibition of nitric oxide synthase slows heart rate recovery from cholinergic activation. J Appl Physiol 1998, 84:1596-1603.
31. Smith K.E., Walker M.W., Artymyshyn R., Bard J., Borowsky B., Tamm J.A., et al. Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G-protein inwardly rectifying K+ channels. J Biol Chem 1998, 273:23321-23326.
32. Dumont Y., Cadieux A., Doods H., Pheng L.H., Abounader R., Hamel E., et al. BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. Br J Pharmacol 2000, 129:1075-1088.
33. Kobayashi E., Nakano H., Morimoto M., Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 1989, 159:548-553.
34. Chijiwa T., Mishima A., Hagiwara M., Sano M., Hayashi K., Inoue T., et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 1990, 265:5267-5272.
35. Bartfai T., Langel U., Bedecs K., Andell S., Land T., Gregersen S., et al. Galanin-receptor ligand M40 peptide distinguishes between putative galanin-receptor subtypes. Proc Natl Acad Sci U S A 1993, 90:11287-11291.
36. Elfvin L.G., Hokfelt T., Bartfai T., Bedecs K. Immunohistochemical demonstration of galanin-, and galanin message-associated peptide-like immunoreactivities in sympathetic ganglia and adrenal gland of the guinea pig. Microsc Res Tech 1994, 29:131-142.
37. Habecker B.A., Gritman K.R., Willison B.D., Van Winkle D.M. Myocardial infarction stimulates galanin expression in cardiac sympathetic neurons. Neuropeptides 2005, 39:89-95.
38. Ewert T.J., Gritman K.R., Bader M., Habecker B.A. Post-infarct cardiac sympathetic hyperactivity regulates galanin expression. Neurosci Lett 2008, 436:163-166.
39. Grenback E., Hulting A.L., Bucht E. Galanin in human plasma. Neuropeptides 2005, 39:337-340.
40. Pernow J., Lundberg J.M., Kaijser L., Hjemdahl P., Theodorsson-Norheim E., Martinsson A., et al. Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. Clin Physiol 1986, 6:561-578.
41. Ulman L.G., Potter E.K., McCloskey D.I. Effects of sympathetic activity and galanin on cardiac vagal action in anaesthetized cats. J Physiol 1992, 448:225-235.
42. Smith-White M.A., Wallace D., Potter E.K. Sympathetic-parasympathetic interactions at the heart in the anaesthetised rat. J Auton Nerv Syst 1999, 75:171-175.
43. Ulman L.G., Moriarty M., Potter E.K., McCloskey D.I. Galanin antagonist effects on cardiac vagal inhibitory actions of sympathetic stimulation in anaesthetized cats and dogs. J Physiol 1993, 464:491-499.
44. Legakis I.N., Mantzouridis T., Saramantis A., Phenekos C., Tzioras C., Mountokalakis T. Human galanin secretion is increased upon normal exercise test in middle-age individuals. Endocr Res 2000, 26:357-364.
45. Carey D.G., Iismaa T.P., Ho K.Y., Rajkovic I.A., Kelly J., Kraegen E.W., et al. Potent effects of human galanin in man: growth hormone secretion and vagal blockade. J Clin Endocrinol Metab 1993, 77:90-93.
46. degli Uberti E.C., Ambrosio M.R., Bondanelli M., Trasforini G., Margutti A., Valentini A., et al. Human galanin reduces plasma norepinephrine levels in man. J Clin Endocrinol Metab 1995, 80:1894-1898.
47. degli Uberti E.C., Bondanelli M., Margutti A., Ambrosio M.R., Valentini A., Campo M., et al. Acute administration of human galanin in normal subjects reduces the potentiating effect of pyridostigmine-induced cholinergic enhancement on release of norepinephrine and pancreatic polypeptide. Neuroendocrinology 1996, 64:398-404.
48. Wetzel G.T., Brown J.H. Relationships between choline uptake, acetylcholine synthesis and acetylcholine release in isolated rat atria. J Pharmacol Exp Ther 1983, 226:343-348.
49. Seebeck J., Schmidt W.E., Kilbinger H., Neumann J., Zimmermann N., Herzig S. PACAP induces bradycardia in guinea-pig heart by stimulation of atrial cholinergic neurones. Naunyn Schmiedebergs Arch Pharmacol 1996, 354:424-430.
50. Herring N., Paterson D.J. Nitric oxide-cGMP pathway facilitates acetylcholine release and bradycardia during vagal nerve stimulation in the guinea-pig in vitro. J Physiol 2001, 535:507-518.
51. Herring N., Zaman J.A., Paterson D.J. Natriuretic peptides like NO facilitate cardiac vagal neurotransmission and bradycardia via a cGMP pathway. Am J Physiol Heart Circ Physiol 2001, 281:H2318-H2327.
52. Balasubramaniam A.A. Neuropeptide Y family of hormones: receptor subtypes and antagonists. Peptides 1997, 18:445-457.
53. Wang S., Hashemi T., Fried S., Clemmons A.L., Hawes B.E. Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry 1998, 37:6711-6717.
54. Heredia M.P., Fernandez-Velasco M., Benito G., Delgado C. Neuropeptide Y increases 4-aminopyridine-sensitive transient outward potassium current in rat ventricular myocytes. Br J Pharmacol 2002, 135:1701-1706.
55. Merriam L.A., Parsons R.L. Neuropeptide galanin inhibits omega-conotoxin GVIA-sensitive calcium channels in parasympathetic neurons. J Neurophysiol 1995, 73:1374-1382.
56. Danson E.J., Zhang Y.H., Sears C.E., Edwards A.R., Casadei B., Paterson D.J. Disruption of inhibitory G-proteins mediates a reduction in atrial beta-adrenergic signaling by enhancing eNOS expression. Cardiovasc Res 2005, 67:613-623.
57. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009, 54:690-697.
58. Ng G.A., Brack K.E., Patel V.H., Coote J.H. Autonomic modulation of electrical restitution, alternans and ventricular fibrillation initiation in the isolated heart. Cardiovasc Res 2007, 73:750-760.
59. Danson E.J., Paterson D.J. Enhanced neuronal nitric oxide synthase expression is central to cardiac vagal phenotype in exercise-trained mice. J Physiol 2003, 546:225-232.
60. Danson E.J., Mankia K.S., Golding S., Dawson T., Everatt L., Cai S., et al. Impaired regulation of neuronal nitric oxide synthase and heart rate during exercise in mice lacking one nNOS allele. J Physiol 2004, 558:963-974.
61. Cole C.R., Blackstone E.H., Pashkow F.J., Snader C.E., Lauer M.S. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 1999, 341:1351-1357.